Vermillion Presents Critical Data From Its OVA1 Clin... ( Study Presented at Society o...)

Vermillion Presents Critical Data From Its OVA1 Clinical Trial

Date:2/10/2009

Study Presented at Society of Gynecologic Oncologists' 40th Annual Meeting - on Women's Cancer

FREMONT, Calif., Feb. 10 /PRNewswire-FirstCall/ -- Vermillion, Inc. (OTC Bulletin Board: VRML), a molecular diagnostics company, presented data from its prospective OVA1 clinical trial at the Society of Gynecologic Oncologists' (SGO) 40th Annual Meeting on Women's Cancer in San Antonio, TX (Poster 196). The study entitled "A biomarker panel for distinguishing between malignant and benign ovarian tumors" was co-authored by Fred Ueland, MD, Associate Professor of Gynecologic Oncology at the University of Kentucky and Principal Investigator of the OVA1 clinical trial, and Zhen Zhang, PhD, Associate Professor of Pathology at the Johns Hopkins University School of Medicine as well as Vermillion scientists.

Details of the poster are available in the attached link "A biomarker panel for distinguishing between malignant and benign ovarian tumors." The primary aim of the study was to determine the ability of our proprietary OvaCalc algorithm to estimate the risk of malignancy in pre and postmenopausal women who are scheduled for surgery with an ovarian mass. The data demonstrates that the OvaCalc algorithm can effectively identify women with a higher likelihood of malignancy. Within the study population, the OvaCalc algorithm also detected 90% of Stage I epithelial ovarian cancer cases and 100% of stage 2-4 cancers while maintaining a greater than 90% negative predictive value among both premenopausal and postmenopausal patients.

"We are extremely pleased with the significant results of the OVA1 prospective clinical trial. A major strength of the OVA1 prospective clinical trial was its inclusion of patients seen at a variety of clinical settings where the inten
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
2. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
3. Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
4. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
5. Vermillion Receives Award From the Society of Gynecologic Oncologists
6. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
7. EntreMed Presents Initial Clinical Results for ENMD-2076
8. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
9. Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
10. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
11. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology

Post Your Comments:

(Date:3/15/2010)... MELBOURNE, Australia , March 15 ... (NYSE: LLY ) and Acrux ... entered into an exclusive worldwide license agreement ... underarm testosterone solution (proposed tradename AXIRON™). The ... under regulatory review by the U.S. Food ...

(Date:3/15/2010)... Kettering Health Network is ... a new testing process developed by DIATHERIX ... the time it takes to detect H1N1, ... and other infectious diseases. Kettering Medical Center ... the network to use the testing system ...

(Date:3/15/2010)... , March 15 According ... InstaPoll, a majority of hospitals believe they are ... supplies. With pending healthcare reforms and proposed cuts ... increased demands from the government and patients this ... less. As healthcare organizations look for ways to ...

[0] Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux [0] Kettering Health Network Partners With DIATHERIX Laboratories To Improve Quality, Efficiency of Care [0] Craneware-Sponsored Panel to Focus on Preventing Revenue Leakage for Chargeable Supplies

... Researchers at Baylor College of,Medicine and ... of Roche Applied,Science, today have published details ... capturing targeted regions of the genome via,NimbleChip(TM) ... technology, called "sequence capture," enables fast and,accurate ...

... First FDA Approved Oral Therapy Will Allow Patients to be Treated ... ... GlaxoSmithKline (NYSE:,GSK) announced today approval by the U.S. Food and Drug ... cell lung cancer (SCLC). Specifically, HYCAMTIN capsules are indicated for ...

Other Medicine Technology:Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions 2 Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions 3 Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions 4 GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer 2 GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer 3 GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer 4

Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer

(Date:3/16/2010)... but one study puts cost per life-year gained at ... -- New chemotherapy agents for metastatic colon cancer improve ... , Researchers at Emory University in Atlanta analyzed data ... metastatic colon cancer between 1995 and 2005. Compared to ... one or more of the six chemotherapy agents approved ...

(Date:3/16/2010)... later, many men weren,t bothered by treatment,s effects, study ... The balance between using enough radiation to shield patients ... bay may not be as tricky as once thought, ... appear to lessen with time. In fact, 10 years ... severe side effects after doctors boosted their radiation to ...

(Date:3/16/2010)... Study found one in two went without, while 87% ... March 16 (HealthDay News) -- Older colon cancer patients ... life-prolonging chemotherapy following surgery for their illness, a new ... advanced colon cancer who are over the age of ... more likely to receive less chemotherapy even when they ...

(Date:3/16/2010)... sell only items that are handpicked to meet a very stringent ... anything is purchased that does not meet these criteria they will ... parents over 1500 carefully vetted products for their babies & children, ... ... (PRWEB) March 16, 2010 -- More and more people are ...

(Date:3/16/2010)... March 16 On Monday, ... Public Health Reports will host a "Meet ... Be." Dr. David Kindig , Emeritus Professor of ... Health Sciences at the University of Wisconsin ... states might expect their mortality rates to be lowered ...

Breaking Medicine News(10 mins):Health News:Are New Chemo Treatments Cost-Effective? 2 Health News:Prostate Cancer Radiation Side Effects May Subside With Time 2 Health News:Older Colon Cancer Patients Less Likely to Get Chemo 2 Health News:Older Colon Cancer Patients Less Likely to Get Chemo 3 Health News:Older Colon Cancer Patients Less Likely to Get Chemo 4 Health News:Safe Baby Promise Offered by Franklin Goose 2 Health News:Public Health Reports Will Host A 'Meet the Author!' Webcast Entitled 'How Healthy Could a State Be' 2

[0] Are New Chemo Treatments Cost-Effective?[0] Prostate Cancer Radiation Side Effects May Subside With Time [0] Older Colon Cancer Patients Less Likely to Get Chemo [0] Safe Baby Promise Offered by Franklin Goose [0] Public Health Reports Will Host A 'Meet the Author!' Webcast Entitled 'How Healthy Could a State Be'

... 8 Sector 10, Inc. (OTC,Bulletin Board: SECT; Frankfurt: ... milestone schedule to start this month with Syptec Internet,Services ... The,deployment is being largely based on private digital alarm ... and is set to scale as large,as 50-53,000 concurrent ...

... almost fivefold, German study finds , , TUESDAY, July 8 ... the more likely it will spread or reoccur, according ... research in the August edition of The Lancet ... tumor thickness were almost five times more likely to ...

... one of the major challenges of the 21st century ... health care systems. Recently, common pathways of the two ... dementia have been suggested. Today there is tremendous interest ... step in the disease cascade or even prevent the ...

... ANGELES, July 8 , WHAT: City of ... 8th,annual La Gota de la Vida campaign to ... treatment institution for cancer and other,life-threatening diseases. The ... National Bone Marrow Registry. This year,s activities,will include ...

... 8 The VHA,Foundation, a foundation focused on ... and the National Business Group on Health (NBGH), ... employers,devoted exclusively to finding innovative solutions to health ... award that recognizes health,systems who are taking a ...

... & Johnson,will host a conference call for financial ... 15, 2008, to review second-quarter results. Dominic,Caruso, Vice ... Vice President, Investor Relations, will host the call., ... the broadcast by,visiting the Company,s website at ...

Other Medicine News:Health News:Announcement Outlines 36 Month Custom Deployment Contract With Potential Revenues Reaching $30 Million Dollars 2 Health News:Paul Rodriguez, Voces Del Rancho and More to Be Honored at the 8th Annual Angels of Hope Awards, July 12 2 Health News:Two National Health Organizations to Recognize the Nation's Best Health Systems for Patient Safety Leadership 2 Health News:Two National Health Organizations to Recognize the Nation's Best Health Systems for Patient Safety Leadership 3

Announcement Outlines 36 Month Custom Deployment Contract With Potential Revenues Reaching $30 Million Dollars Thickness, Location Predict Skin Cancer's Spread Antihypertensive treatment on cognitive functions in Alzheimer's disease Paul Rodriguez, Voces Del Rancho and More to Be Honored at the 8th Annual Angels of Hope Awards, July 12 Two National Health Organizations to Recognize the Nation's Best Health Systems for Patient Safety Leadership Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results

... System is a rapid, real-time thermal cycler ... samples. By automating much of the testing ... programmable, it is the fastest, easiest to ... the market. The SmartCycler delivers highly accurate ...

... Real Time Thermal Block and its ... such as quantification of gene expression, ... and validation of microarray results. Exicycler ... between two molecules, such as protein-protein ...

... converts any DNA Engine thermal cycler into a ... any of our user-changeable sample blocks. The small ... to keep pace with the evolving needs of ... Engine base units, new or existing. The Chromo4 ...

Mx3000P instrument, desktop computer, Mx3000P software package, user's manual, one Brilliant QPCR Reagent of your choice, and custom filter wheel with 4 filters chosen from: FAM/SYBR Green I, TET, HE...

Medicine Products:

SmartCycler® 3200 System Exicycler™ Real-time Thermal Block Chromo 4 Four-Color Real-Time System Mx3000P Real-Time PCR System (110 volt) with Desktop Computer

Vermillion Presents Critical Data From Its OVA1 Clin...( Study Presented at Society o...),Health